Hikma Pharmaceuticals Plc (LON:HIK) had its price objective reduced by J P Morgan Chase & Co from GBX 1,500 ($19.72) to GBX 1,250 ($16.43) in a report published on Friday morning. They currently have a neutral rating on the stock.

HIK has been the subject of several other reports. Jefferies Group LLC lowered their price objective on Hikma Pharmaceuticals Plc from GBX 1,450 ($19.06) to GBX 1,390 ($18.28) and set an underweight rating for the company in a research note on Wednesday, June 28th. Barclays PLC lowered their price objective on Hikma Pharmaceuticals Plc from GBX 2,200 ($28.92) to GBX 1,500 ($19.72) and set an overweight rating for the company in a research note on Friday, August 25th. Goldman Sachs Group, Inc. (The) lowered Hikma Pharmaceuticals Plc to a neutral rating and lowered their price objective for the company from GBX 2,600 ($34.18) to GBX 1,310 ($17.22) in a research note on Tuesday, August 22nd. HSBC Holdings plc lowered their price objective on Hikma Pharmaceuticals Plc from GBX 1,700 ($22.35) to GBX 1,410 ($18.54) and set a reduce rating for the company in a research note on Tuesday, June 27th. Finally, Citigroup Inc. reaffirmed a neutral rating and issued a GBX 1,550 ($20.38) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and a consensus target price of GBX 1,551.45 ($20.40).

Hikma Pharmaceuticals Plc (HIK) opened at 1185.00 on Friday. The stock’s market capitalization is GBX 2.84 billion. The firm has a 50-day moving average price of GBX 1,199.64 and a 200-day moving average price of GBX 1,533.74. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1,101.00 and a 52 week high of GBX 2,346.00.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/hikma-pharmaceuticals-plc-hik-given-new-gbx-1250-price-target-at-j-p-morgan-chase-co/1620508.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.